Increased global travel, expansion of large cities and changing climates are just a few of many factors that can impact the geographical distribution and incidence of disease carrying vectors, such as ticks and mosquitoes.
The emergence and spread of vector-borne diseases can pose a significant threat to local communities. However, globalization has enabled disease to spread further and more efficiently than ever before. In resource-limited countries, the lack of accessibility to reliable detection methods of vector-borne diseases aids to the transmission cascade. One method to help reduce the spread of infectious diseases is by implementing blood screening programs with state-of-the-art technologies that can detect life-threatening pathogens, ensuring that global blood supplies are safe before transfusion.
Roche offers a comprehensive assay menu to detect a wide variety of vector-borne diseases, including West Nile Virus (WNV), Babesiosis, Zika, Chagas, Chikungunya and Dengue fever. This portfolio runs on fully automated high-volume systems which offer the possibility to run laboratory developed tests to support the identification of emerging infections.